Blog Archive
-
▼
2008
(66)
-
▼
February
(13)
- Genfit and Pierre Fabre, alliance
- UCB and sanofi-aventis, FDA Approves XYZAL® (levoc...
- LFB and the French Rare Diseases Alliance, Partner...
- IPSOGEN, Genomic Grade to improve Breast Cancer di...
- Sanofi Pasteur and Statens Serum Institut , develo...
- NOVEXEL AND FOREST LABORATORIES, LICENSE AGREEMENT...
- Trophos, grant from The Michael J. Fox Foundation ...
- Servier, Medicinal Chemistry Research Center in Bu...
- Faust Pharmaceuticals, Research Agreement with Takeda
- Tornier and Bioset Collaborate on Products for Ort...
- Novagali Pharma, FDA Clearance of IND for US Clini...
- Ipsen, a Biologics License Application (BLA) for D...
- Cerep, to provide profiling services to support a ...
-
▼
February
(13)
Thursday, February 14, 2008
Trophos, grant from The Michael J. Fox Foundation to evaluate compounds in Parkinson’s disease model
Marseille, February 8th, 2008- Trophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurological disorders, announces today that The Michael J. Fox Foundation (MJFF) has awarded the company a Therapeutics Development Initiative grant to pursue the evaluation of compounds preventing mitochondrial dysfunction to treat Parkinson’s disease (PD)... Trophos' Press Release - Michael J. Fox Foundation's Press Release-